Help Patients Get to Goal With Heart Failure Meds

January 2023

Questions will come up about the best way to titrate meds for heart failure with reduced ejection fraction (HFrEF).

Less than 1% of patients are on target-dose “triple therapy” with an ACEI, ARB, or Entresto (sacubitril/valsartan)...an evidence-based beta-blocker (carvedilol, etc)...and an aldosterone antagonist.

Even fewer get the latest guideline-recommended “quad therapy” for HFrEF...by adding an SGLT2 inhibitor (Farxiga, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote